Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AMG 951 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| C | OTHER | 40 subjects will receive up to 6 cycles of carboplatin (AUC=6.0mg/ml.min) and paclitaxel (200mg/m2) on day 1 of each 21 day cycle plus Bevacizumab (15mg/kg) on day 1 of each 21 day cycle until disease progression, study drug intolerability or withdrawal of consent. |
| E | EXPERIMENTAL | 40 subjects will receive up to 6 cycles of carboplatin (AUC=6.0mg/ml.min) and paclitaxel (200mg/m2) on day 1 of each 21 day cycle plus Bevacizumab (15mg/kg) on day 1 and AMG 951 (rhApo2L/TRAIL) (20mg/kg) on days 1-2 per 21 day cycle until disease progression, study drug intolerability or withdrawal of consent. |
| B | EXPERIMENTAL | 40 subjects will receive up to 6 cycles of carboplatin (AUC=6.0mg/ml.min) and paclitaxel (200mg/m2) on day 1 of each 21 day cycle plus AMG 951 (rhApo2L/TRAIL) (8mg/kg) for 5 days per 21 days cycle until disease progression, study drug intolerability or withdrawal of consent. |
| A | OTHER | 40 subjects will receive up to 6 cycles of Carboplatin (AUC = 6.0mg/ml.min) and Paclitaxel (200mg/m2) only |
| D | EXPERIMENTAL | 40 subjects will receive up to 6 cycles of carboplatin (AUC=6.0mg/ml.min) and paclitaxel (200mg/m2) on day 1 of each 21 day cycle plus Bevacizumab (15mg/kg) on day 1 and AMG 951 (rhApo2L/TRAIL) (8mg/kg) on days 1-5 per 21 day cycle until disease progression, study drug intolerability or withdrawal of consent. |
| Name | Type | Description |
|---|---|---|
| AMG 951 (rhApo2L/TRAIL) | DRUG | AMG 951 is recombinant human Apo2Ligand/Tumor necrosis factor related apoptosis inducing ligand (rhApo2L/TRAIL) that triggers apoptosis through activation of death receptor 4 (DR4) and death receptor 5 (DR5). |
| Bevacizumab | DRUG | Bevacizumab is a recombinant humanized version of a murine antibody to vascular endothelial growth factor (VEGF). |
| Carboplatin | DRUG | Standard platinum based chemotherapy |
| Paclitaxel | DRUG | Standard taxane chemotherapy |
Inclusion Criteria: * Histologically or cytologically confirmed Non-Small Cell Lung Cancer (NSCLC). Mixed tumors will be categorized by the predominant cell type unless small cell elements are present in which case the patient is ineligible. Cytologic or histologic elements can be established on me...
Top 20 of 84 competitors
AMG 951 is an investigational small molecule being studied for the treatment of non-small cell lung cancer (NSCLC). It is being developed by Amgen Inc. and is currently in Phase 2 clinical development. The drug is not approved and remains under investigation for this indication.
AMG 951 is being developed by Amgen Inc., a biopharmaceutical company traded on the NASDAQ under the ticker AMGN. The drug is an investigational small molecule in Phase 2 clinical development for non-small cell lung cancer.
AMG 951 is in Phase 2 clinical development. It is an investigational small molecule being studied for non-small cell lung cancer. The drug is not approved and is still undergoing clinical trials to evaluate its safety and efficacy.
AMG 951 has one completed Phase 2 clinical trial, NCT00508625, which enrolled 213 participants with previously untreated non-small cell lung cancer. The study evaluated AMG 951 in combination with chemotherapy, with or without bevacizumab. The trial was controlled and randomized but not double-blind.
AMG 951 is also known as rhApo2L/TRAIL. In clinical trial NCT00508625, the drug is referred to as AMG 951 [rhApo2L/TRAIL]. This alternative name may appear in scientific literature and trial registries.